Tigris Pharmaceuticals Initiates Randomized Phase 2 Study Of AFP-464 In ER-Positive B

		HER2 Support Group Forums > Breast Cancer Newsfeed
Tigris Pharmaceuticals Initiates Randomized Phase 2 Study Of AFP-464 In ER-Positive B

05-27-2011, 01:06 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 20,138	Tigris Pharmaceuticals Initiates Randomized Phase 2 Study Of AFP-464 In ER-Positive B Tigris Pharmaceuticals, Inc., announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 (aminoflavone prodrug) with or without Faslodex® (fulvestrant) in estrogen receptor (ER)-positive breast cancer patients... More...

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Forum Rules

All times are GMT -7. The time now is 05:50 AM.